|Articles|May 7, 2013

Greenphire Announces New London Office to Facilitate Expansion in Europe

Greenphire

, the leading provider of payment technologies for the clinical trials industry, today announced an expansion into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and isdesigned to support the increasing global demand for Greenphire’s products and services.

The expansion reflects the commercial and operational success Greenphire has enjoyed in the last two years. Both global payment technology platforms for Patient and Investigator payments have seen increased adoption within the life sciences industry and the new office in London will play a critical role in continuing to build on the growth Greenphire has experienced.

Sam Whitaker, Founder and CEO, comments “We are excited to execute on this key part of our 2013 strategic plan. Establishing our presence in Europe allows us to support our Enterprise clients in those areas where they conduct research and development, facilitates stronger support of the many clinical investigators conducting research on behalf of biopharmaceutical companies and provides abase from which we can grow our commercial presence in Europe.”

The new UK office address is: Greenphire, 1 EastPoultry Avenue, London, EC1A 9PT, United Kingdom and the London office number is: +44 (0) 208 150 6470


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.